BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36396609)

  • 1. Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper.
    Goldhardt O; Freiberger R; Dreyer T; Willner L; Yakushev I; Ortner M; Förstl H; Diehl-Schmid J; Milz E; Priller J; Ramirez A; Magdolen V; Thaler M; Grimmer T
    Alzheimers Dement; 2023 May; 19(5):2117-2134. PubMed ID: 36396609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of aberrant amyloid β and phosphorylated tau expression in herpes simplex virus-infected neurons of the trigeminal ganglia and brain.
    Tran DN; Bakx ATCM; van Dis V; Aronica E; Verdijk RM; Ouwendijk WJD
    Brain Pathol; 2022 Jul; 32(4):e13044. PubMed ID: 34913212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.
    Krut JJ; Zetterberg H; Blennow K; Cinque P; Hagberg L; Price RW; Studahl M; Gisslén M
    J Neurol; 2013 Feb; 260(2):620-6. PubMed ID: 23052602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?
    Sacchi L; Carandini T; Fumagalli GG; Pietroboni AM; Contarino VE; Siggillino S; Arcaro M; Fenoglio C; Zito F; Marotta G; Castellani M; Triulzi F; Galimberti D; Scarpini E; Arighi A
    J Alzheimers Dis; 2022; 85(3):1009-1020. PubMed ID: 34897084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
    Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
    Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions.
    Vogelgsang J; Wedekind D; Bouter C; Klafki HW; Wiltfang J
    J Alzheimers Dis; 2018; 62(1):203-212. PubMed ID: 29439341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
    Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
    Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-β and p-Tau Anti-Threat Response to Herpes Simplex Virus 1 Infection in Primary Adult Murine Hippocampal Neurons.
    Powell-Doherty RD; Abbott ARN; Nelson LA; Bertke AS
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
    Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
    Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of fluid biomarkers in Alzheimer's Disease.
    Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
    Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
    Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
    Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.